Geron Corp. buy klostergang
Start price
26.06.15
/
50%
€3.58
Target price
07.12.15
€4.50
Performance (%)
29.46%
End price
07.12.15
€4.63
Summary
This prediction ended on 07.12.15 with a price of €4.63. The prediction had a final performance of 29.46%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 4.823% | 4.823% | 23.070% | -52.182% |
| iShares Core DAX® | 2.992% | 3.220% | 4.271% | 53.697% |
| iShares Nasdaq 100 | -1.584% | -3.172% | 24.749% | 76.697% |
| iShares Nikkei 225® | -2.254% | -9.924% | 43.518% | 60.793% |
| iShares S&P 500 | -0.009% | 1.641% | 20.967% | 62.807% |
Comments by klostergang for this prediction
In the thread Geron Corp. diskutieren
Mit JNJ-Partnerschaft und Orphan Drug der FDA gegen Krebs :
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.